Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Those too slim to be eligible for injections can no longer get prescription without seeing a doctor under new guidance ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

For years, obesity was often seen as a result of poor lifestyle choices. However, experts now suggest that biological factors ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

Research tells us that eating enough protein and staying physically active can be helpful in reducing the amount of non-fat ...

New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...

From Aug. 1 to the end of the year, Medicaid beneficiaries received 33,035 claims for GLP-1 drugs for weight loss, a number ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

As Mom loses weight with semaglutide, this letter writer struggles through her incessant food commentary at mealtimes.